We report herein a set of 3'-azido-3'-deoxythymidine (AZT) derivatives based on triazoles and triazolium salts for HIV1 infection. Compounds were tested with using HIV1 pre-exposure prophylaxis experimental model. All compounds were able to decrease infection and two of them were able to clear almost all the infection, suggesting that these drugs could play an important role in pre-exposure prophylaxis therapies.
Introduction
The extraordinary development of therapies for Human Immunodeficiency Virus (HIV) treatment over the last decades has extensively reduced the morbidity and mortality associated with the disease. At present, there are over 30 drugs utilized for the treatment of HIV, divided into five main classes, which target different steps in the viral life cycle: 1) viral entry; 2) reverse transcription; 3) integration and 4) viral maturation. However, current therapies are compromised by the rapid emergence of resistant strains, side effects resulting from extended use of drugs and their poor bioavailability [1] [2] [3] . The development of more cost effective drugs, with increased efficiency and lower side effects is therefore mandatory. AZT (3'-azido-3'-deoxythymidine) was the first approved drug for the treatment of t HIV 1 . AZT is a nucleoside Reversed transcriptase inhibitor, in which the 3'-OH of the deoxiribose moiety is absent and operates as an obligate chain terminator 1 . Long-term use of AZT is associated with a significant number of side effects, including myopathy, cardiomyopathy, and anemia, among others 2 . AZT is generally used as part of the so-called highly active retroviral therapy (HAART) in combination with lamivudine and abacavir 4 , still used to date.
Appropriate modification of AZT can be used as a tool to increase the efficiency of the drug and introduce additional functionalities to further increase its rage of activity. The presence of an azide group replacing 3'-OH of the deoxyribose converts AZT in a suitable substrate for further modification by the introduction of triazole groups, known to be active as antivirals in their own right 5, 6 . Wang et all showed that modified triazoles can main features which a azole derived AZT must contain to present antiviral activity are a bulky aromatic ring and a 1,5-substitution pattern on the triazole 7 . Nevertheless, the utilization of 1,4 triazoles with sterically demanding substrates also present anti-viral properties, indicating that sterics are probably one of the main driving forces for their activity. In addition, further modifications of AZT within the sugar can also activate or block a specific function, via further modification of the sugar 6 . Herein we report the synthesis of novel AZT derivatives based on triazoles and their antiviral activity against HIV-1, utilizing two methodologies to measure antiviral activity, e.g. using infected cells with and without pre-exposure to the drugs.
Results and Discussion
We synthesized 1,4 triazoles and 1,5 triazoles via 1,3-Huisgen cycloaddition with different substituents and, using both Cu(I) and Ru(II) catalysts, to obtain 1,4 and 1,5 derivatives, respectively 8 .
For 1,4-triazoles, AZT reacts with the corresponding alkyne with the Cu(I) catalyst (5%) at 100 ºC for 2h, in a mixture of tert-butanol:water (1:1). For 1,5-triazoles require somewhat longer reaction times (24 hours) using a similar protocol with Ru(II)(C 5 Me 5 )(PPh 3 )Cl (5%) at 100 ºC in dioxane. In both cases, purification via silica gel chromatography is required. Compounds are obtained in good to moderate isolated yields (50 to 80%).
Aiming to understand how the anti-viral activity is linked to the two methods utilized in this work, we synthesized two standard 1,4-and 1,5-phenyl derivatives, 1 and 3, as well compound 6, previously reported, for comparative purposes 7 .
To confirm the structures of the compounds, NMR studies ( possible. This synthetic variability could in principle improve physiological solubility, due to the existence of a delocalized positive charge at the triazole and formation of a salt. Thus, we synthesized the corresponding triazolium salts derived from compounds 1-7 using methyl iodide or methyl triflate, to obtain the triazolium salts 8 and 9. The compounds were obtained in moderate yields (50-60%). Their formation was also confirmed by NMR studies and MS. In the 1 H NMR, and when compared to the corresponding triazoles, a significant downfield shift of circa 1 ppm is also observed for the aromatic C-H of the triazole ring. This feature is diagnostic of N3 quaternization, and formation positive charge on the nitrogen that is delocalized within the triazole ring, inducing the deshielding of the H trz proton. In addition, a new singlet appears in the region δ 3.5-4.5 ppm indicative of the presence of the methyl group at N3.
Anti-Viral Activity
Next, we determined the ability of the compounds synthesized to block HIV-1 replication in human primary CD4 T cells isolated from peripheral blood and finally of healthy donors Two main methods were tested as depicted in Fig. 4 , in the first one we tested their anti-retroviral capacity once HIV-1 replication had already initiated (method 1), while in the second methodology we tested their ability to act as pre-exposure prophylaxis treatment we pre-treated CD4 T cells with AZT derivatives for the 18 hours prior to HIV-1 infection (method 2). The percentage of HIV-1 infected cells were determined in live CD4 T cells, according to the gating strategy outlined in Fig. 5 . Part of the compounds was tested with these two methodologies, and the results can be found bellow. We found that AZT derivatives have modest effects in HIV-1 replication once primary round of infection had been established (method 1). Nevertheless, compounds 2 and 6 seem to be able to partially halt ongoing HIV-1 ongoing replication. We obtained far more promising results with AZT derivatives in our pre-exposure prophylaxis experimental model (method 2). In this latter experimental approach, all compounds tested were able to decrease HIV-1 infection rates for at least one half, and remarkably compounds 6 and 7 were able to clear almost all infection.
Regarding the activity of 1,4-versus 1,5-triazoles, these results indicate that there is no significant difference between their antiviral activity for method 1, with the two most active compounds are compounds 2 and 6. As for the activity of the triazolium salts, our observations indicate that there methylation decreases antiviral activity. These preliminary results are in line with previous reports regarding the activity of 1,5-triazoles derived from AZT, with compound 6 reported by Wang 7 presenting high antiviral activity for the two methods utilized.
Conclusions
Despite the efficacy of AZT, the search of other HIV-1 reverse transcription inhibitors has continued due to AZT poor bioavailability at the sites of HIV-1 replication (lymphoid organs), the emergence of HIV-1 resistant strains and secondary effects. Here we describe novel AZT derivatives modified with triazoles that are particularly efficient if provided prior to HIV-1 infection. All compounds were able to decrease infection and two of them, compounds 6 and 7, were able to clear almost all the infection. Our preliminary results suggest that these drugs could play an important role not only in HIV-1 treatment but also in pre-exposure prophylaxis therapies. Further derivatization of AZT is currently being pursued and will be reported in due course.
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